New trends in dermatological treatment

Published on 04/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 977 times

New trends in dermatological treatment

Therapeutic advances have revolutionized the treatment of skin disease over the last 40 years. The 1960s saw the introduction of topical steroids, the 1970s the development of psoralen with ultraviolet A (PUVA), the 1980s retinoids, and the 1990s lasers and ciclosporin. The major advance of the ‘noughties’ was the biologics.

There have been changes in the delivery of care. Over the last two decades, the number of inpatient dermatology beds has fallen dramatically and in some places disappeared altogether. Patients who would have been admitted are now managed as outpatients with potent drugs. Nurse practitioners have a higher profile and run their own clinics, e.g. for patients with leg ulcers, eczema or psoriasis, prescribe treatments and perform surgical procedures.

Atopic eczema

The topical immunomodulators (calcineurin inhibitors) tacrolimus (Protopic) and pimecrolimus (Elidel) are alternatives to topical steroids and do not cause skin atrophy (Fig. 1). The systemic immunosuppressors mycophenolate mofetil and methotrexate (the latter often used in psoriasis) may be beneficial in severe atopic eczema.

image

Fig. 1 Skin atrophy with purpura due to excessive topical use of a potent steroid.

Bullous diseases

Intravenous immunoglobulin is used for severe pemphigus or mucous membrane pemphigoid. The biologic rituximab has been used in resistant cases (p. 33). Oral doxycycline may be effective in pemphigoid.

Cutaneous T cell lymphoma

The retinoid receptor agonist bexarotene (Targretin) is effective in some patients with cutaneous T cell lymphoma. Photophoresis, in which a lymphocyte-enriched blood fraction from the patient who has taken a psoralen is exposed to UVA outside the body and then re-infused, is sometimes effective, especially for the Sézary syndrome (p. 44).

Erythema nodosum

Thalidomide can be considered in unresponsive cases. A pregnancy prevention programme is required in women of child-bearing age owing to the known teratogenic effects. Thalidomide may also be beneficial in Behçet’s disease and recurrent erythema multiforme.

Fungal infections

Terbinafine (Lamisil) cream, applied once or twice daily for 1 week, cures tinea pedis (Fig. 2). Pulse treatment with oral itraconazole (Sporanox), terbinafine (Lamisil) or fluconazole (Diflucan) has given cure rates of 80% for fungal infection of the toenails. Three-weekly pulses of terbinafine (Lamisil) given over 8 weeks produce a 90% cure rate for childhood tinea capitis (Fig. 3).

image

Fig. 2 Tinea pedis.

image

Fig. 3 Kerion with associated alopecia.

The boggy pustular lesion results from a zoophilic fungal infection (p. 66).

Hand dermatitis

Alitretinoin (Toctino), an oral retinoid, was recently introduced as the first systemic treatment approved for use in severe chronic hand dermatitis unresponsive to potent topical steroid treatment, provided the patient satisfies the criteria of severity and impaired quality of life (DLQI) score. Alitretinoin is usually given in a dose of 30 mg daily for 12–24 weeks (depending on response). In a clinical trial, total or near complete clearance was seen in 48% of patients after 24 weeks of therapy. In women of child-bearing potential, a pregnancy-prevention programme is followed as alitretinoin is teratogenic. The most common side-effect is headaches. Regular monitoring of blood lipids and thyroid function is required.

Hidradenitis suppurativa

Hidradenitis suppurativa (p. 65) is characterized by abscesses, sinuses and scars in the axillae and groin (Fig. 4) and is very difficult to treat. Acitretin is helpful in suitable patients, as can be the combination of the antibiotics clindamycin and rifampicin. Recently, infliximab infusion has been used with success (p. 33).

image

Fig. 4 Hidradenitis suppurativa.

Multiple inflammatory nodules are evident. Scarring is common.

Hyperhidrosis

The injection of botulinum toxin A (Botox, Dysport) into the axillary or palmar skin will control excessive sweating in these areas (p. 65), but needs to be repeated every 9 months.

Leg ulcers

Larval therapy with sterile maggots (LarvE) can be used for managing sloughy leg ulcers (p. 72). Recombinant platelet-derived growth factor (becaplermin) is licensed for use in neuropathic ulcers, e.g. in diabetes. Tissue-engineered skin equivalents, e.g. Apligraf, can be effective in therapy-resistant wounds.

Psoriasis

The biologics have revolutionized the treatment of severe psoriasis (p. 19). Other systemic approaches to consider in difficult to manage cases where biologics may be contraindicated or have failed include the fumaric acid esters and mycophenolate mofetil.

Scabies

Ivermectin, a drug used to treat onchocerciasis (p. 61), may be effective for scabies, especially of the crusted (Norwegian) type (p. 118) and for use in institutional outbreaks.

Scleroderma

Topical calcipotriene (0.005%) has been shown to improve lesions of localized scleroderma (morphoea). Oral methotrexate is beneficial in certain types of morphoea, e.g. en coup de sabre. Systemic sclerosis (Fig. 5) can respond to photophoresis (see above) and PUVA.

image

Fig. 5 Systemic sclerosis of the face.

Telangiectasia and furrowing around the mouth are prominent changes.

Skin cancer

Topical use of the immunomodulator imiquimod (Aldara) is effective for actinic keratosis, in situ squamous cell carcinoma and superficial basal cell carcinoma. ‘Sentinel’ lymph node biopsy is now becoming an accepted part of management of patients with malignant melanoma of greater than 1 mm Breslow thickness. Dacarbazine and interferon-α are used in the chemotherapy of metastatic malignant melanoma. The use of ipilimumab, a biologic that blocks cytotoxic T cell-associated antigen 4, is being studied in patients with metastatic malignant melanoma.

Toxic epidermal necrolysis

The use of high-dose intravenous immunoglobulin (1–2 g/kg daily for 3–4 days), started early, may be helpful in toxic epidermal necrolysis.

Vitiligo

The Excimer 308-nm laser (Fig. 6) is effective in the treatment of localized areas of vitiligo affecting the cosmetically sensitive sites, e.g. the face.

image

Fig. 6 The Excimer 308-nm laser.

It can be used for treating localized areas of vitiligo, psoriasis or cutaneous T cell lymphoma.

New trends in dermatological treatment

Disease Topical therapy Systemic therapy
Atopic eczema Pimecrolimus, tacrolimus Mycophenolate, methotrexate
Bullous disease – Immunoglobulin, rituximab, doxycycline
Cutaneous T cell lymphoma
Erythema nodosum		 –
–		 Bexarotene, photophoresis
Thalidomide
Fungal infection Terbinafine Pulse itraconazole, terbinafine, fluconazole
Hand dermatitis – Alitretinoin
Hidradenitis suppurativa – Acitretin, clindamycin/rifampicin, infliximab
Hyperhidrosis Botulinum toxin (intralesional) –
Leg ulcer Sterile larvae, skin equivalent –
Psoriasis – Biologics, fumaric acid esters, mycophenolate mofetil
Scabies – Ivermectin
Scleroderma Calcipotriene Methotrexate, photophoresis
Skin cancer Imiquimod (superficial basal cell carcinoma) Dacarbazine/interferon-α (malignant melanoma)
Toxic epidermal necrolysis – Immunoglobulin
Vitiligo – Excimer laser

Web resource

http://www.nice.org.uk/

Related posts:

Ultraviolet radiation and the skin Molecular genetics and the skin Body image, the psyche and the skin Vasculitis and the reactive erythemas Basics of medical therapy Skin cancer – Malignant melanoma